Effects of Cholecalciferol vs Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone

Albert Shieh, Christina Ma, R. Chun, Sten Witzel, Brandon Rafison, H. Contreras, Jonas Wittwer-Schegg, L. Swinkels, Tonnie Huijs, M. Hewison, J. Adams
{"title":"Effects of Cholecalciferol vs Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone","authors":"Albert Shieh, Christina Ma, R. Chun, Sten Witzel, Brandon Rafison, H. Contreras, Jonas Wittwer-Schegg, L. Swinkels, Tonnie Huijs, M. Hewison, J. Adams","doi":"10.1210/jc.2016-3919","DOIUrl":null,"url":null,"abstract":"Context\nVitamin D deficiency disproportionately affects nonwhite individuals. Controversy persists over how to best restore low 25D levels, and how to best define vitamin D status [total (protein bound plus free) vs free 25D].\n\n\nObjective\nTo assess the effects of vitamin D3 (cholecalciferol, or D3) vs 25-hydroxyvitamin D3 (calcifediol, or 25D3) on total and free 25D in a multiethnic cohort of adults, and whether change in parathyroid hormone (PTH) is more strongly associated with total vs free 25D.\n\n\nDesign\nSixteen-week randomized controlled trial. Biochemistries at 0, 4, 8, and 16 weeks.\n\n\nSetting\nAcademic medical center.\n\n\nParticipants\nThirty-five adults ≥18 years of age with 25D levels <20 ng/mL.\n\n\nIntervention\nSixty micrograms (2400 IU)/d of D3 or 20 μg/d of 25D3.\n\n\nMain Outcome Measures\nTotal and free 25D, and PTH.\n\n\nResults\nBaseline total (16.2 ± 3.7 vs 17.0 ± 2.5 ng/mL; P = 0.4) and free (4.2 ± 0.8 vs 4.7 ± 1.0 pg/mL; P = 0.2) 25D were similar between D3 and 25D3 groups, respectively; 25D3 increased total (+25.5 vs +13.8 ng/mL; P = 0.001) and free (+6.6 vs +3.5 pg/mL; P = 0.03) 25D more than D3. By 4 weeks, 87.5% of 25D3 participants had total 25D levels ≥30 ng/mL, compared with 23.1% of D3 participants (P = 0.001). Change in PTH was associated with both total (P = 0.01) and free 25D (P = 0.04).\n\n\nConclusions\n25D3 increased total and free 25D levels more rapidly than D3, regardless of race/ethnicity. Free and total 25D were similarly associated with change in PTH.","PeriodicalId":22632,"journal":{"name":"The Journal of Clinical Endocrinology & Metabolism","volume":"120 1","pages":"1133–1140"},"PeriodicalIF":0.0000,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"41","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Clinical Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jc.2016-3919","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 41

Abstract

Context Vitamin D deficiency disproportionately affects nonwhite individuals. Controversy persists over how to best restore low 25D levels, and how to best define vitamin D status [total (protein bound plus free) vs free 25D]. Objective To assess the effects of vitamin D3 (cholecalciferol, or D3) vs 25-hydroxyvitamin D3 (calcifediol, or 25D3) on total and free 25D in a multiethnic cohort of adults, and whether change in parathyroid hormone (PTH) is more strongly associated with total vs free 25D. Design Sixteen-week randomized controlled trial. Biochemistries at 0, 4, 8, and 16 weeks. Setting Academic medical center. Participants Thirty-five adults ≥18 years of age with 25D levels <20 ng/mL. Intervention Sixty micrograms (2400 IU)/d of D3 or 20 μg/d of 25D3. Main Outcome Measures Total and free 25D, and PTH. Results Baseline total (16.2 ± 3.7 vs 17.0 ± 2.5 ng/mL; P = 0.4) and free (4.2 ± 0.8 vs 4.7 ± 1.0 pg/mL; P = 0.2) 25D were similar between D3 and 25D3 groups, respectively; 25D3 increased total (+25.5 vs +13.8 ng/mL; P = 0.001) and free (+6.6 vs +3.5 pg/mL; P = 0.03) 25D more than D3. By 4 weeks, 87.5% of 25D3 participants had total 25D levels ≥30 ng/mL, compared with 23.1% of D3 participants (P = 0.001). Change in PTH was associated with both total (P = 0.01) and free 25D (P = 0.04). Conclusions 25D3 increased total and free 25D levels more rapidly than D3, regardless of race/ethnicity. Free and total 25D were similarly associated with change in PTH.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胆钙化醇与钙化二醇对总25-羟基维生素D和游离25-羟基维生素D及甲状旁腺激素的影响
维生素D缺乏症对非白人的影响尤为严重。关于如何最好地恢复低25D水平,以及如何最好地定义维生素D状态[总(蛋白质结合加上游离)vs游离25D]的争议一直存在。目的评估维生素D3(胆钙化醇,或D3)与25-羟基维生素D3(钙化二醇,或25D3)对多种族成人总25D和游离25D的影响,以及甲状旁腺激素(PTH)的变化是否与总25D和游离25D有更强的相关性。设计16周随机对照试验。第0、4、8、16周的生化课。学术医疗中心。参与者:35名年龄≥18岁且25D水平<20 ng/mL的成年人。干预:服用60微克(2400国际单位)/天的D3或20微克/天的25D3。主要观察指标:总25D、游离25D、甲状旁腺激素。结果基线总浓度(16.2±3.7 vs 17.0±2.5 ng/mL);P = 0.4)和游离(4.2±0.8 vs 4.7±1.0 pg/mL;P = 0.2) 25D在D3组和25D3组之间差异无统计学意义;25D3增加总剂量(+25.5 vs +13.8 ng/mL);P = 0.001)和游离(+6.6 vs +3.5 pg/mL;P = 0.03) 25D以上。到4周时,87.5%的25D3参与者的总25D水平≥30 ng/mL,而D3参与者的比例为23.1% (P = 0.001)。PTH的变化与总25D (P = 0.01)和游离25D (P = 0.04)相关。结论无论种族/民族,25d3均比D3更快地提高总25D和游离25D水平。游离和总25D与PTH的变化相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Treatment Preferences in Patients with Hypothyroidism: an Analysis of Eleven Randomized Controlled Trials. Metabolomics: A Promising Tool in the Prevention, Diagnosis, and Treatment of Obesity. Association between papillary thyroid cancer and primary aldosteronism in individuals with hypertension. The changing treatment paradigm in prolactinoma - a prospective series of 100 consecutive neurosurgical cases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1